FOLH1 and neuropathy: In conjunction with the previously described beneficial effects of GCPII inhibition in diabetic and chemotherapy-induced neuropathy [12], [13], the data support the possible broad therapeutic utility of GCPII inhibition in alleviating the symptoms of peripheral nervous system injuries.